A canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease-associated pain

Table 1 Enrolled dog demographic summary on D0 of study (treatment day)

	NV-01	Placebo	P-value for comparison of treatment groups
Age, years	10 (4-14)	10 (4-16)	0.795 (Wilcoxon Rank Sums)
Sex	8FS; 4MC; 1M	5FS; 7MC; 1M	0.470 (Pearson)
Weight, kilograms	27.0 (16.3-40.5)	30.2 (19.9-44.8)	0.209 (ChiSq)
Body condition score (median)	5 (5-8)	6 (5-7)	0.713 (Wilcoxon Rank Sums)

ISSN: 1746-6148